Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chanelle McCoy Health is an Irish pharmaceutical-standard biotech company focused on the development and commercialization of ultra-pure, synthetic cannabidiol (CBD) products. Founded by Chanelle McCoy and Caroline Glynn, the company operates primarily under the brand name Pureis, offering a range of CBD oils, capsules, and topicals. The company distinguishes itself in the crowded CBD market by adhering to rigorous pharmaceutical standards, being the first brand to receive Novel Food validation from both the Food Standards Agency (UK) and the European Food Safety Authority. Their products are backed by extensive clinical safety and bioavailability data, targeting wellness areas such as sleep, anxiety, and pain management. By utilizing synthetic CBD, the company ensures a product that is 100% free of THC, pollutants, and toxins commonly found in plant-derived extracts.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chanelle McCoy Health.